Korean J Intern Med.
2014 Sep;29(5):577-579. 10.3904/kjim.2014.29.5.577.
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
- Affiliations
-
- 1Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. seungki73@catholic.ac.kr
- KMID: 1794621
- DOI: http://doi.org/10.3904/kjim.2014.29.5.577
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Small Molecule Inhibitors in Rheumatoid Arthritis
- Current concepts in the management of rheumatoid arthritis
- Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
- Treatment strategy for patients with rheumatoid arthritis
- Guidelines for Prevention of Tuberculosis in Patients with Rheumatoid Arthritis Treated with TNF-alpha Blockers
